IRIS
RINALDI, SILVIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.500
EU - Europa 427
AS - Asia 88
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.016
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.500
IT - Italia 84
UA - Ucraina 84
IE - Irlanda 78
SE - Svezia 75
DE - Germania 43
TR - Turchia 33
SG - Singapore 29
DK - Danimarca 23
FI - Finlandia 23
KR - Corea 13
GB - Regno Unito 12
IN - India 7
CN - Cina 6
BE - Belgio 3
CH - Svizzera 1
EU - Europa 1
RU - Federazione Russa 1
Totale 2.016
Salva come PNG Salva come JPEG
Città #
Chandler 236
Fairfield 168
Ashburn 153
Jacksonville 134
Dublin 78
Seattle 77
Wilmington 71
Woodbridge 67
Houston 64
New York 60
Des Moines 56
Cambridge 50
Ann Arbor 31
Lawrence 30
Princeton 30
San Mateo 29
Turin 21
Washington 16
Boardman 13
San Diego 13
Helsinki 12
Norwalk 8
Pune 6
Falls Church 5
Saint Louis 5
Beijing 4
Castelraimondo 3
Kilburn 3
Montegiorgio 3
Brussels 2
Chengdu 2
Hounslow 2
London 2
Sassari 2
Acquaviva Picena 1
Ancona 1
Bevagna 1
Chicago 1
Chiswick 1
Islington 1
Liège 1
Marche 1
Milan 1
New Bedfont 1
New Delhi 1
Porto 1
San Benedetto Del Tronto 1
San Severino Marche 1
Totale 1.470
Salva come PNG Salva come JPEG
Nome #
The role of an immune checkpoint score in resected non-small cell lung cancer patients' prognosis 128
The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases 103
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 82
Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. 79
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 79
Electrolyte disorders in cancer patients: a systematic review 79
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review 77
Hyponatremia in cancer patients: Time for a new approach 74
Managing hyponatremia in lung cancer: latest evidence and clinical implications 74
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 74
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy 74
Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. 72
Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma 72
Risk of hyponatraemia in cancer patients treated with targeted therapies: A systematic review and meta-analysis of clinical trials 70
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 68
Medical treatment for gastro-entero-pancreatic neuroendocrine tumours 67
Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach? 64
Systemic treatment for lung carcinoids: from bench to bedside 64
High CTLA-4 expression correlates with poor prognosis in thymoma patients 64
The Formidable Metamorphosis of the Salamander’s Wool: Asbestos from Eternal Material to Awful Pathologies 63
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 61
Syndrome of inappropriate antidiuresis in prostate adenocarcinoma with neuroendocrine differentiation: a case report and literature review 59
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer 57
Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients 56
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 55
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 55
Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study 54
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 52
Lung cancer prognosis: Can histological patterns and morphological features have a role in the management of lung cancer patients? 51
Treatment of advanced small cell lung cancer 47
Totale 2.074
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.126
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.126
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20195 0 0 0 0 0 0 0 0 0 4 1 0
2019/2020152 0 0 12 0 16 0 15 1 19 17 20 52
2020/2021620 40 62 61 2 126 34 51 74 45 44 46 35
2021/2022228 17 34 16 1 4 25 7 14 19 26 26 39
2022/2023622 34 86 36 72 20 113 0 43 142 0 61 15
2023/2024309 52 7 32 14 49 110 4 41 0 0 0 0
Totale 2.074